Willingness to pay for innovation: the case of the anti-HCV drugs from the Italian National Health Service perspective:

Global & Regional Health Technology Assessment

Francesco SaverioMennini¹ 

关键词: Anti-HCV drugs;    Chronic HCV;    Effectiveness;    Innovative drugs;    Willingness to pay;   

DOI  :  10.5301/GRHTA.5000201

学科分类：医学（综合）

来源: Sage Journals

【 摘 要 】

IntroductionThe hepatitis C virus (HCV) induces several pathological conditions with a substantial medical and economic burden. Currently licensed treatments for HCV infection include pegylated and standard interferon alpha (IFN), ribavirin (RBV), the protease inhibitors boceprevir, telaprevir, and boceprevir. A new scenario of therapy for HCV infection is being established following new treatments approval. The aim of this study is to evaluate new strategies long-term health outcomes and the willingness to pay for new anti-HCV treatments from the Italian societal perspective.MethodsA multistate morbidity-mortality model was developed to estimate the infection progression in a theoretical cohort of Italian subjects. The Markov model considered 12 health states (F0, F1, F2, F3, Compensated cirrhosis (F4), SVR, decompensated cirrhosis, HCC, Transplantation (1 year), Transplantation (years later), HCV-related death and death from other causes) and 42 transition probabilities. The model was fed with data from...

【 授权许可】

CC BY